SCHEDULE 13G: Morgan Stanley Discloses 6.0% Passive Stake in Marinus Pharmaceuticals

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed a Schedule 13G disclosing a passive beneficial ownership of 6.0% in Marinus Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, collectively reported beneficial ownership of 3,298,215 shares of Marinus Pharmaceuticals, Inc. Common Stock.
• This aggregate amount represents 6.0% of the class of Marinus Pharmaceuticals, Inc. Common Stock.
• The filing was made under Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Morgan Stanley reported shared voting power over 3,298,115 shares and shared dispositive power over 3,298,215 shares.
• Morgan Stanley & Co. LLC reported shared voting power over 3,297,507 shares and shared dispositive power over 3,297,507 shares.
• Morgan Stanley is classified as a Parent Holding Company (HC) and Corporation (CO), while Morgan Stanley & Co. LLC is classified as a Broker or Dealer (BD) and Corporation (CO).
• The filing confirms that Morgan Stanley & Co. LLC, a wholly-owned subsidiary of Morgan Stanley, owns the securities being reported by Morgan Stanley as a parent holding company.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's performance or outlook. The filing explicitly states the stake is passive and not for control.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Marinus Pharmaceuticals, Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major financial institution, Morgan Stanley, in a pharmaceutical company. Such disclosures are routine for institutional investors crossing certain ownership thresholds and typically reflect portfolio management decisions rather than strategic corporate actions related to the issuer's industry position.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can influence market perception and liquidity.
• Company Management: Informs management of significant passive ownership by a major financial institution.

Key Dates

Keywords

Marinus Pharmaceuticals, Morgan Stanley, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Pharmaceuticals, Healthcare